Vaccine adjuvants: Scientific challenges and strategic initiatives

Expert Review of Vaccines

Volumn 8, Issue 3, 2009, Pages 293-298

  Harandi, Ali M ^a   Davies, Gwyn ^b   Olesen, Ole F ^c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c EUROPEAN COMMISSION   (Belgium)

Author keywords

AdjuNet; Adjuvant; EAAC; EMEA; European Commission; GADI; Innate immunity; Mucosal immunity; Toll like receptor; Vaccine

Indexed keywords

CHOLERA VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; ORAL POLIOMYELITIS VACCINE; PREPANDRIX; ROTAVIRUS VACCINE; TOLL LIKE RECEPTOR; TYPHOID VACCINE; UNCLASSIFIED DRUG; VACCINE; WART VIRUS VACCINE; IMMUNOGLOBULIN RECEPTOR;

ADAPTIVE IMMUNITY; DRUG SAFETY; HUMAN; INNATE IMMUNITY; PRIORITY JOURNAL; REVIEW; VACCINE PRODUCTION; ANIMAL; IMMUNOLOGY; MEDICAL RESEARCH;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BIOMEDICAL RESEARCH; HUMANS; RECEPTORS, IMMUNOLOGIC; VACCINES;

EID: 63849177560     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.8.3.293     Document Type: Review

References (29)

1. Lindblad E. Aluminium compounds for use in vaccines. Immunol. Cell Biol. 82, 497-805 (2004).
2. Hem S, Hogenesch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev. Vaccines 6(5), 685-698 (2007).
3. Lindblad, E. Aluminium adjuvants - in retrospect and prospect. Vaccine 22, 3658-3668 (2004). • Good review on aluminium adjuvants.
4. O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev. Vaccines 6(5), 699-710 (2007).
5. Stanberry LR. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 11(Suppl. 3), 161A-169A (2004).
6. Bovier PA, Epaxal: a virosomal vaccine to prevent hepatitis A infection. Expert Rev. Vaccines 7(8), 1141-1150 (2008).
7. Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines 6(5), 723-739 (2007).
8. Carter NJ, Plosker GL. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus. Biodrugs 22, 279-292 (2008).
9. Ishii KJ, Akira S. Toll or Toll-free adjuvant path toward the optimal vaccine development. J. Clin. Immunol. 27, 363-371 (2007).
10. Kumagai Y, Takeuchi O, Akira S. Pathogen recognition by innate receptors. J. Infect. Chemother 14, 86-92 (2008). • Good review on pathogen-recognition receptors.
11. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316, 1628-1632 (2007).
12. Zughaier SM, Zimmer SM, Datta A, Carlson RW, Stephens DS. Differential induction of the Toll-like receptor 4-MyD88-dependent and -independent signaling pathways by endotoxins. Infect. Immun. 73, 2940-2950 (2005).
13. Gavin AL, Hoebe K, Duong B et al. Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling. Science 314, 1936-1938 (2006). •• Excellent study reporting the induction of potent antibody response by some standard adjuvants in the absence of Toll-like receptor signaling.
14. DeFrancesco L. Dynavax trial halted. Nat. Biotechnol. 26, 484 (2008).
15. Verstraeten T, Descamps D, David MP et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 26, 6630-6638 (2008). • Report on a large integrated safety study of the AS04 adjuvanted vaccines conducted by GlaxoSmithKline.
16. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge Nat. Rev. Immunol. 6, 148-158 (2006). •• Excellent review on mucosal immunity and vaccines.
17. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat. Med. 11, S45-S53 (2005). • Good overview on immunity, vaccine and tolerance in the mucosa.
18. Dennehy PH. Rotavirus vaccines: an overview. Clin. Microbiol. Rev. 21, 198-208 (2008).
19. Belshe R, Lee MS, Walker RE, Stoddard J, Mendelman PM. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev. Vaccines 3(6), 643-654 (2004).
20. Mutsch M, Weigong Zhou MPH, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350, 896-903 (2004),
21. Frech SA, Dupont HL, Bourgeois AL et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a Phase II, randomised, double-blind, placebo-controlled field trial. Lancet 371, 2019-2025 (2008).
22. Holmgren J, Harandi AM, Czerkinsky C. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Expert Rev. Vaccines 2(2), 205-217 (2003).
23. Peppoloni S, Ruggiero P, Contorni M et al. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev. Vaccines 2(2), 285-293 (2003).
24. EMEA/CHMP/VEG/134716/2004 Guideline on adjuvants in vaccines for human use www.emea.europa.eu
25. EAAC: European Adjuvant Advisory Committee www.eaac.com
26. GADI: The Global Adjuvant Development Initiative www.adjunet.net
27. TB-Vac project www.TB-vac.org
28. EMVDA: European Malaria Vaccine Development Association www.emvda.org
29. MUVAPRED: Mucosal Vaccines for Poverty Related Diseases www.mucosalimmunity.org/muvapred